Clinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemic

Basit Öğe Kaydı
dc.authoridAslan Kayıran, Melek/0000-0003-4347-3134
dc.authoridSarikaya Solak, Sezgi/0000-0002-8572-8249
dc.authoridTopaloglu Demir, Filiz/0000-0002-2049-1316
dc.authorwosidAslan Kayıran, Melek/F-2840-2018
dc.authorwosidPolat Ekinci, Algün/JDW-8990-2023
dc.authorwosidSarikaya Solak, Sezgi/A-4789-2016
dc.contributor.authorDemir, Filiz Topaloglu
dc.contributor.authorEkinci, Algun Polat
dc.contributor.authorAytekin, Sema
dc.contributor.authorTopkarci, Zeynep
dc.contributor.authorKayiran, Melek Aslan
dc.contributor.authorAkbulut, Tugba Ozkok
dc.contributor.authorTopal, Ilteris Oguz
dc.date.accessioned2024-06-12T11:08:11Z
dc.date.available2024-06-12T11:08:11Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackgroundSince psoriasis is a chronic disease, it is not recommended to discontinue the treatment agents used. However, in real life, the treatment of psoriasis patients may be interrupted for various reasons. During the pandemic period, the treatment of many patients was also interrupted. ObjectivesTo evaluate relapse and clinical worsening in psoriasis patients whose biological therapy was interrupted during the pandemic and reveal associated factors. MethodsThe study included patients aged >= 18 years, who were followed up with moderate and severe chronic psoriasis controlled by the last biological agent [Psoriasis Area Severity Index (PASI) 75 response achieved] but had to discontinue their treatment during the pandemic. The patients' demographic and clinical characteristics, clinical course after the discontinuation of these agents, presence of clinical worsening, and relapse were evaluated. Risk factors were analyzed with the logistic regression analysis. ResultsThe study included 169 patients, with a mean age of 47.3 +/- 14.5 (18-87) years. The mean biologics-free time was 18.2 +/- 12.3 (2-56) weeks. Clinical worsening was detected in 41.4% and relapse in 48.5% of the patients. The significant risk factors for clinical worsening and relapse in both univariate and multivariate analyses were alcohol use during the biologics-free period, total time off biologics, and the presence of an additional triggering factor. The use of secukinumab and ustekinumab was found to be a protective factor against clinical worsening in multivariate analyses. ConclusionAs the biologics-free period is prolonged, the likelihood of clinical worsening and relapse increases, therefore, we do not recommend discontinuing biological agents.en_US
dc.identifier.doi10.1111/jocd.15638
dc.identifier.endpage731en_US
dc.identifier.issn1473-2130
dc.identifier.issn1473-2165
dc.identifier.issue3en_US
dc.identifier.pmid36630728en_US
dc.identifier.scopus2-s2.0-85146251492en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage722en_US
dc.identifier.urihttps://doi.org/10.1111/jocd.15638
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22341
dc.identifier.volume22en_US
dc.identifier.wosWOS:000912688300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of Cosmetic Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMedical Therapyen_US
dc.subjectPsoriasisen_US
dc.subjectTreatmenten_US
dc.subjectRegistryen_US
dc.subjectTherapyen_US
dc.subjectSafetyen_US
dc.titleClinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemicen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu